Skip to content

KLRS KLRS Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

Merck & Co. logo
Merck & Co.MRK
-$460.25M+20.9%
Amgen logo
AmgenAMGN
-$959M-9.7%
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
$571K-88.5%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-$8.44M-64.1%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$4.56M+93.5%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
-$4.12M-78.3%

Other financials

Income statement

See full
Operating income-$11.8M-14.3%
Net income-$10.9M-6.5%
EPS (diluted)-$0.46+81.7%

Balance sheet

See full
Cash & equivalents$34.4M-65.9%
Total debt$1.4M
Total equity$68.6M+7.3%
Total assets$109.8M+6.5%

Cash flow

See full
Operating cash flow-$11.6M-55.6%
CapEx$17.0K
Free cash flow-$7.1M

Valuation

See full
Market cap$96.83M+136%
Enterprise value$63.82M

Returns & leverage

See full
Return on equity-66.6%
Debt / equity
Current ratio12.2×-2.1×

Where this comes from

Reported directly by KLRS in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.

The official record: KLRS’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KLRS's change in accrued liabilities?
KLRS (KLRS) reported change in accrued liabilities of $120K in Q1 2026.
How has KLRS's change in accrued liabilities changed year-over-year?
KLRS's change in accrued liabilities increased by 1600.0% year-over-year, from -$8K to $120K.
What does change in accrued liabilities mean?
Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.